New insider activity at CalciMedica ( (CALC) ) has taken place on August 18, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CMO Sudarshan Hebbar has made a significant investment in CalciMedica by purchasing 5,976 shares of the company’s stock, valued at $16,340.
Spark’s Take on CALC Stock
According to Spark, TipRanks’ AI Analyst, CALC is a Underperform.
CalciMedica’s low stock score reflects its financial challenges, including zero revenue and negative cash flows. However, technical indicators suggest the stock is currently oversold, providing a potential entry point for risk-tolerant investors. The promising results from the Auxora trial offer a positive outlook, potentially improving future financial performance.
To see Spark’s full report on CALC stock, click here.
More about CalciMedica
YTD Price Performance: -11.55%
Average Trading Volume: 64,336
Technical Sentiment Signal: Hold
Current Market Cap: $40.66M